On July 22, 2025, the US Food and Drug Administration (FDA) started accepting applications to participate in the Commissioner’s National ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Oral, non-opioid drug candidate advancing through Phase 1 and nearing completion of the single ascending dose (SAD) portion ...

Senate Republicans are moving swiftly to clear key hurdles in their effort to pass a set of spending bills before the August recess and get the ball moving toward avoiding a government shutdown in ...

The majority of Teva's business lies in generic and off-patent branded drugs which faces price and volume pressures that will be exacerbated as regulatory actions and other players in the drug supply ...

As a longtime Washington Post reporter and an author of 10 books, he held corporate America accountable for safe ...

These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be ...

A family's persistent efforts in unraveling the cause of their daughter's chronic nerve and muscular maladies led to the ...

When parts of the nervous system start to break down—or get broken—the consequences for human health can be staggering. Can ...

Q2 2025 Earnings Call Transcript July 29, 2025 Kiniksa Pharmaceuticals, Ltd. beats earnings expectations. Reported EPS is ...

Artificial intelligence will free us to do better work, but the world may not be ready for how fast it's growing, Microsoft ...

Immutep is continuing the AIPAC-003 trial, which enrolled 71 metastatic hormone receptor positive (HR+), HER2-negative/low or ...